HTA Archives - Pharmaphorum

Orphan drugs: overcoming barriers to market access

August 22, 2017

What manufacturers should consider, after successfully overcoming any HTA hurdles, to achieve market access.

Orphan drugs: overcoming barriers to market access

https://pharmaphorum.com/views-and-analysis/orphan-drugs-overcoming-barriers-market-access/

Orphan drugs: overcoming HTA barriers to access

August 15, 2017

How can orphan drug manufacturers demonstrate value and improve access to drugs?

Orphan drugs: overcoming HTA barriers to access

https://pharmaphorum.com/views-and-analysis/orphan-drugs-overcoming-hta-barriers-access/

Demonstrating value – the future for market access

August 3, 2017

With the US joining other countries around the world in demanding definitions and measurements of the value of

Demonstrating value – the future for market access

https://pharmaphorum.com/views-and-analysis/demonstrating-value-future-market-access/

Immuno-oncology drugs: key to the Cancer Moonshot?

June 21, 2017

Assessing the global challenges inhibiting immuno-oncology market access.

Immuno-oncology drugs: key to the Cancer Moonshot?

https://pharmaphorum.com/views-and-analysis/immuno-oncology-drugs-key-cancer-moonshot/

Behind the buzz of real-world data and real-world evidence

April 5, 2017

Putting the who, where and why of real-world studies into context.

Behind the buzz of real-world data and real-world evidence

https://pharmaphorum.com/views-and-analysis/behind-buzz-real-world-data-real-world-evidence/

NICE ‘pauses’ plans to introduce charges for pharma

January 19, 2017

Plans by NICE to start charging pharma companies for appraising their medicines are to be ‘paused’ in order

NICE ‘pauses’ plans to introduce charges for pharma

https://pharmaphorum.com/news/nice-pauses-plans-introduce-charges-pharma/

Budget impact and cost effectiveness: alternatives to NICE and NHSE proposals

January 17, 2017

A new way to capture when drugs are ‘cost effective’ but not ‘affordable’ looks set to be introduced in England.

Budget impact and cost effectiveness: alternatives to NICE and NHSE proposals

https://pharmaphorum.com/views-and-analysis/budget-impact-cost-effectiveness-alternatives-nice-nhse-proposals/

The budget impact of new medicines

January 10, 2017

What could be the impact of proposed new ‘budget impact threshold’ for drugs?

The budget impact of new medicines

https://pharmaphorum.com/views-and-analysis/budget-impact-new-medicines/

Fast-track appraisals and Managed Access Agreements

December 23, 2016

Experts discuss England’s proposed ‘fast-track’ appraisals for new treatments, plus MAAs.

Fast-track appraisals and Managed Access Agreements

https://pharmaphorum.com/views-and-analysis/fast-track-appraisals-managed-access-agreements/

Trending

HTA

Orphan drugs: overcoming barriers to market access

Orphan drugs: overcoming HTA barriers to access

Demonstrating value – the future for market access

Immuno-oncology drugs: key to the Cancer Moonshot?

Behind the buzz of real-world data and real-world evidence

NICE ‘pauses’ plans to introduce charges for pharma

Budget impact and cost effectiveness: alternatives to NICE and NHSE proposals

The budget impact of new medicines

Fast-track appraisals and Managed Access Agreements

CDD for Biologics Summit 2017

Neoantigen Summit 2017

ICI Summit Europe 2017

6th International GMP, GCP & Quality Control Summit

Inhalation and Respiratory Drug Products Summit

3rd Annual Pre-Filled Syringes Summit

Search

Advanced Search

Trending

HTA